Literature DB >> 32851445

Percutaneous vertebroplasty of the cervical spine performed via a posterior trans-pedicular approach.

Roberto Luigi Cazzato1, Pierre de Marini2, Pierre Auloge2, Pierre Alexis Autreausseau2, Guillaume Koch2, Danoob Dalili3,4, Pramod Rao5, Julien Garnon2, Afshin Gangi2.   

Abstract

OBJECTIVES: Percutaneous vertebroplasty (PV) of the cervical spine has been traditionally performed with a trans-oral or antero-lateral approach. The posterior trans-pedicular approach (PTPA) has been sporadically reported. Therefore, the aim of this study is to retrospectively assess the technical feasibility, safety, and clinical outcomes of cervical PV performed with a PTPA.
METHODS: All consecutive patients undergoing PV in cervical levels with PTPA (under general anesthesia and computed tomography [CT] guidance) from January 2008 to November 2019 were identified. The following data were collected: patients' demographics; indication for PV; vertebral level features; procedure-related variables; and clinical outcomes including complications and pain relief.
RESULTS: Thirty-two patients (18 females, 14 males; mean age 61.1 ± 13.2 years, range 36-88) were included accounting for 36 vertebrae. Three vertebrae (3/36, 8%) were referred due to an underlying traumatic fracture, the remaining (33/36, 92%) due to a painful lytic tumor. Technical success was 97% (35/36 levels). Mean time required to deploy the trocar was 23 ± 11 min (range 7-60). Extra-vertebral asymptomatic cement leakage was observed in 3/35 (9%) vertebral levels. One patient (1/32, 3%) developed an acute cardiogenic pulmonary edema requiring admission in the intensive care unit; another patient (1/32, 3%) developed localized infection to the skin entry site, which was managed conservatively. At 1-month follow-up, the mean pain in the study population was 1.0 ± 1.1 (range 0-4/10) vs 6.2 ± 1.4 (range 4-9/10) at baseline (p < 0.05).
CONCLUSIONS: Cervical PV performed via a CT-guided PTPA is technically feasible, safe, and results in effective pain relief. KEY POINTS: • Percutaneous vertebroplasty (PV) is a well-established technique for the treatment of benign and malignant compression fractures. • Common PV approaches used for cervical vertebrae include the trans-oral, antero-lateral, lateral, and sporadically the posterior trans-pedicular approach. • Retrospective analysis of our 11-year experience with the posterior trans-pedicular approach used for cervical vertebrae proved that such approach was safe and effective.

Entities:  

Keywords:  Cervical vertebrae; Spinal neoplasms; Vertebroplasty

Mesh:

Substances:

Year:  2020        PMID: 32851445     DOI: 10.1007/s00330-020-07198-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  1 in total

1.  CT-guided percutaneous vertebroplasty of the upper cervical spine via a translateral approach.

Authors:  Wen-Hao Guo; Mao-Bin Meng; Xin You; Yong Luo; Jun Li; Meng Qiu; Zheng-Yin Liao
Journal:  Pain Physician       Date:  2012 Sep-Oct       Impact factor: 4.965

  1 in total
  3 in total

1.  CT-Guided Percutaneous Vertebroplasty of the Cervico-Thoracic Junction for the Management of Pathologic Fracture or Symptomatic Lytic Lesion in Cancer Patients.

Authors:  Benjamin Moulin; Vincent Servois; Jonathan Dbjay; Guillaume Dutertre; Laura Thery; Carole Bouleuc; Timothee Marchal; Celine Laouisset; Alexis Burnod; Jeremy Smadja; Herve Brisse
Journal:  Cardiovasc Intervent Radiol       Date:  2021-12-01       Impact factor: 2.740

2.  Vessel-Plasty Using Bone-Filling Mesh Container for Treatment of Malignant Severe Compression Fractures in Cervical Vertebrae.

Authors:  Yue Yang; Qinghua Tian; Tao Wang; Yingying Lu; Wenbin Li; Chungen Wu
Journal:  J Pain Res       Date:  2022-04-21       Impact factor: 2.832

3.  Study on the Relationship between the Use of Bisphosphonates for Antiosteoporosis and Vertebral Re-Fracture after Vertebroplasty.

Authors:  Li Qian; Qian Chen; Dashou Wang; Qi Pan; Qianhong Jian; Yinghong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-23       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.